FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912598009> ?p ?o ?g. }

• W2912598009 endingPage "e0211122" @default.
• W2912598009 startingPage "e0211122" @default.
• W2912598009 abstract "Background and aims The present study aimed to report our real-life experience of the TPO receptor agonist lusutrombopag for cirrhotic patients with low platelet counts. Methods We studied platelet counts in 1,760 cirrhotic patients undergoing invasive procedures at our hospital between January 2014 and December 2017. In addition, we studied 25 patients who were administered lusutrombopag before invasive procedures between June 2017 and January 2018. Effectiveness of lusutrombopag to raise platelet counts and to avoid transfusion and treatment-related adverse events were analyzed. Results In 1,760 cirrhotic patients without lusutrombopag prior to invasive procedures, proportion of patients whose platelet counts <50,000/μL and needed platelet transfusions were 66% (n = 27/41) for radiofrequency ablation, 43% (n = 21/49) for transarterial chemoembolization, and 55% (n = 21/38) for endoscopic injection sclerotherapy / endoscopic variceal ligation, respectively. In 25 cirrhotic patients treated by lusutrombopag prior to the invasive procedures, platelet counts significantly increased compared with baseline (82,000 ± 26,000 vs. 41,000 ± 11,000/μL) (p < 0.01). Out of 25 patients, only 4 patients (16%) needed platelet transfusion before the invasive procedures. The proportion of patients with low platelet count and who needed platelet transfusions was significantly low in patients treated with lusutrombopag compared to those not treated with lusutrombopag (16% (4/25) vs. 54% (69/128), p = 0.001). Platelet counts after lusutrombopag treatment and prior to invasive procedures were lower in patients with a baseline platelet count ≤30,000/μL (n = 8) compared with those with a baseline platelet count >30,000/μL (n = 17) (50,000 ± 20,000 vs 86,000 ± 26,000/μL, p = 0.002). Patients with a baseline platelet count ≤30,000/μL with spleen index (calculated by multiplying the transverse diameter by the vertical diameter measured by ultrasonography) ≥40 cm2 (n = 3) had a lower response rate to lusutrombopag compared to those with spleen index <40 cm2 (n = 5) (0% vs. 100%, p = 0.02). Hemorrhagic complication was not observed. Recurrence of portal thrombosis was observed and thrombolysis therapy was required in one patient who had prior history of thrombosis. Conclusions Lusutrombopag is an effective and safe drug for thrombocytopenia in cirrhotic patients, and can reduce the frequency of platelet transfusions." @default.
• W2912598009 created "2019-02-21" @default.
• W2912598009 creator A5005158019 @default.
• W2912598009 creator A5006957453 @default.
• W2912598009 creator A5009053363 @default.
• W2912598009 creator A5009144885 @default.
• W2912598009 creator A5018535039 @default.
• W2912598009 creator A5024065548 @default.
• W2912598009 creator A5025671725 @default.
• W2912598009 creator A5035807265 @default.
• W2912598009 creator A5053860058 @default.
• W2912598009 creator A5058386183 @default.
• W2912598009 creator A5066924600 @default.
• W2912598009 creator A5067999427 @default.
• W2912598009 creator A5070972892 @default.
• W2912598009 creator A5073094281 @default.
• W2912598009 creator A5077398626 @default.
• W2912598009 creator A5082716780 @default.
• W2912598009 creator A5084405736 @default.
• W2912598009 creator A5085351803 @default.
• W2912598009 date "2019-02-15" @default.
• W2912598009 modified "2023-10-18" @default.
• W2912598009 title "Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures" @default.
• W2912598009 cites W1579337559 @default.
• W2912598009 cites W16457225 @default.
• W2912598009 cites W1973631133 @default.
• W2912598009 cites W2002521678 @default.
• W2912598009 cites W2003981991 @default.
• W2912598009 cites W2026465052 @default.
• W2912598009 cites W2044335440 @default.
• W2912598009 cites W2049949162 @default.
• W2912598009 cites W2064826286 @default.
• W2912598009 cites W2070145271 @default.
• W2912598009 cites W2072960422 @default.
• W2912598009 cites W2080157259 @default.
• W2912598009 cites W2086252784 @default.
• W2912598009 cites W2113917646 @default.
• W2912598009 cites W2121960517 @default.
• W2912598009 cites W2130290858 @default.
• W2912598009 cites W2167147321 @default.
• W2912598009 cites W2183370948 @default.
• W2912598009 cites W2199242724 @default.
• W2912598009 cites W2253621434 @default.
• W2912598009 cites W2335497705 @default.
• W2912598009 cites W2591717879 @default.
• W2912598009 cites W2599190130 @default.
• W2912598009 cites W2615821735 @default.
• W2912598009 cites W2768432470 @default.
• W2912598009 cites W4247810022 @default.
• W2912598009 cites W2336403597 @default.
• W2912598009 doi "https://doi.org/10.1371/journal.pone.0211122" @default.
• W2912598009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6377090" @default.
• W2912598009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30768601" @default.
• W2912598009 hasPublicationYear "2019" @default.
• W2912598009 type Work @default.
• W2912598009 sameAs 2912598009 @default.
• W2912598009 citedByCount "23" @default.
• W2912598009 countsByYear W29125980092019 @default.
• W2912598009 countsByYear W29125980092020 @default.
• W2912598009 countsByYear W29125980092021 @default.
• W2912598009 countsByYear W29125980092022 @default.
• W2912598009 countsByYear W29125980092023 @default.
• W2912598009 crossrefType "journal-article" @default.
• W2912598009 hasAuthorship W2912598009A5005158019 @default.
• W2912598009 hasAuthorship W2912598009A5006957453 @default.
• W2912598009 hasAuthorship W2912598009A5009053363 @default.
• W2912598009 hasAuthorship W2912598009A5009144885 @default.
• W2912598009 hasAuthorship W2912598009A5018535039 @default.
• W2912598009 hasAuthorship W2912598009A5024065548 @default.
• W2912598009 hasAuthorship W2912598009A5025671725 @default.
• W2912598009 hasAuthorship W2912598009A5035807265 @default.
• W2912598009 hasAuthorship W2912598009A5053860058 @default.
• W2912598009 hasAuthorship W2912598009A5058386183 @default.
• W2912598009 hasAuthorship W2912598009A5066924600 @default.
• W2912598009 hasAuthorship W2912598009A5067999427 @default.
• W2912598009 hasAuthorship W2912598009A5070972892 @default.
• W2912598009 hasAuthorship W2912598009A5073094281 @default.
• W2912598009 hasAuthorship W2912598009A5077398626 @default.
• W2912598009 hasAuthorship W2912598009A5082716780 @default.
• W2912598009 hasAuthorship W2912598009A5084405736 @default.
• W2912598009 hasAuthorship W2912598009A5085351803 @default.
• W2912598009 hasBestOaLocation W29125980091 @default.
• W2912598009 hasConcept C126322002 @default.
• W2912598009 hasConcept C141071460 @default.
• W2912598009 hasConcept C197934379 @default.
• W2912598009 hasConcept C2776689292 @default.
• W2912598009 hasConcept C2777377203 @default.
• W2912598009 hasConcept C2778902805 @default.
• W2912598009 hasConcept C71924100 @default.
• W2912598009 hasConcept C89560881 @default.
• W2912598009 hasConcept C90924648 @default.
• W2912598009 hasConceptScore W2912598009C126322002 @default.
• W2912598009 hasConceptScore W2912598009C141071460 @default.
• W2912598009 hasConceptScore W2912598009C197934379 @default.
• W2912598009 hasConceptScore W2912598009C2776689292 @default.
• W2912598009 hasConceptScore W2912598009C2777377203 @default.
• W2912598009 hasConceptScore W2912598009C2778902805 @default.
• W2912598009 hasConceptScore W2912598009C71924100 @default.

• next